| Similar Articles |
|---|
 |
BusinessWeek
March 11, 2010
Margaret Cronin Fisk et al. |
Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.   |
Chemistry World
November 11, 2013
Sarah Houlton |
Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion. |
The Motley Fool
December 22, 2006
Stephen Albainy-Jenei |
Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use. |
BusinessWeek
July 8, 2010
Dexter Roberts |
The Higher Costs of Bribery in China The U.S. is policing the activities of big multinationals in China more aggressively, with China's own prosecutors sometimes following suit. |
The Motley Fool
January 16, 2009
Brian Orelli |
Lilly Pays Up. Big Deal. Lawsuits are just a fact of life when investing in drug companies, and pharmaceutical investors have to expect these kinds of legal defeats. |
Pharmaceutical Executive
May 1, 2005
Robert Ullmann |
Back Page: Unhealthy Justice More than any other healthcare law, the Medicare/Medicaid exclusion statute has distorted our criminal justice system with government fraud investigations. This well-intentioned but misguided law should be repealed. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
February 23, 2009
Brian Orelli |
The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor. |
BusinessWeek
March 31, 2011
David Voreacos et al. |
Johnson & Johnson's Quality Catastrophe After 50-plus product recalls in 15 months, the $60 billion company is fighting to clear its once-trusted name. |
The Motley Fool
October 2, 2007
Billy Fisher |
Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
The Motley Fool
December 31, 2007
Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. |
The Motley Fool
January 31, 2008
Brian Lawler |
A Zettlement for Zyprexa? Eli Lilly may be close to resolving a government lawsuit over improper marketing. |
BusinessWeek
October 18, 2004
John Carey |
"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be? |
Chemistry World
May 29, 2015
Phillip Broadwith |
Achillion partners with Janssen to boost hepatitis C pipeline Janssen will invest $225 million in Achillion shares, and has promised performance milestone payments worth up to $1.1 billion, plus royalties on any sales. |
Pharmaceutical Executive
January 1, 2006
Cinquegrana & Lloyd |
Legal: Shifting Perspective on Off-Label Promotion A recent court case points to the government's shifting perspective on how it prosecutes companies for promoting off-label. Instead of criminal charges, hefty corporate integrity agreements might be in store. |
The Motley Fool
June 11, 2009
Brian Orelli |
Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children. |
The Motley Fool
August 24, 2007
Brian Orelli |
Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note. |
The Motley Fool
March 19, 2008
Brian Lawler |
InterMune Suffers a Postscript The former CEO is indicted, but that shouldn't hurt the drugmaker. |
The Motley Fool
March 11, 2011
Brian Orelli |
Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
November 26, 2007
Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. |
BusinessWeek
December 20, 2004
Amy Barrett |
J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant. |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
January 24, 2006
Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. |
BusinessWeek
January 30, 2006
Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
BusinessWeek
February 25, 2010
Weintraub & Tirrell |
Eli Lilly's Drug Assembly Line Faced with expiring patents that could weaken sales, Lilly is reorganizing for speed. |
BusinessWeek
April 17, 2006
Amy Barrett |
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock. |
BusinessWeek
September 30, 2009
Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. |
BusinessWeek
April 23, 2007
Arlene Weintraub |
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them. |
Chemistry World
March 26, 2014
Phillip Broadwith |
$1.2bn J&J deceptive marketing fine overturned The Arkansas Supreme Court has overturned a lower court's fine of $1.2 billion, imposed on Johnson & Johnson's subsidiary Janssen in April 2012 over its marketing of antipsychotic drug Risperdal (risperidone). |
Pharmaceutical Executive
January 1, 2011
Jill Wechsler |
Politics & PDUFA Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead. |
The Motley Fool
March 10, 2010
Brian Orelli |
Up 160% With Room to Run You've got to love biotech and InterMune. |
BusinessWeek
October 2, 2006
Gene G. Marcial |
Shopping For Schering? The buzz about Schering-Plough on Wall Street is that the company is in play. |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk. |
The Motley Fool
November 5, 2010
Brian Orelli |
Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta. |
The Motley Fool
September 1, 2010
Brian Orelli |
Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge. |
Chemistry World
December 22, 2010
Sarah Houlton |
Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US. |
The Motley Fool
March 23, 2011
Brian Orelli |
Eli Lilly: Great Plan, Poor Execution Eli Lilly shuns large mergers, but hasn't produced drugs on its own. |
The Motley Fool
August 27, 2009
Brian Orelli |
Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan |
Pharmaceutical Executive
February 1, 2013
Jill Wechsler |
Breakthrough Year for New Drugs More new medicines gained market approval, but marketers face resistance from payers looking to cut healthcare spending. |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
October 17, 2007
Brian Orelli |
J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
